Jump to content
 







Main menu
    


Navigation  


●Main page
 ●Contents
 ●Current events
 ●Random article
 ●About Wikipedia
 ●Contact us
 ●Donate
  



Contribute  


●Help
 ●Learn to edit
 ●Community portal
 ●Recent changes
 ●Upload file
  







Search  

































●Create account

●Log in
 









●Create account
 ● Log in
  



Pages for logged out editors learn more  


●Contributions
 ●Talk
  


















Contents

   



(Top)
  


1 References  













Pegsunercept






●فارسی
 ●日本語
 ●Tiếng Việt
  
Edit links
  








●Article
 ●Talk
  
















●Read
 ●Edit
 ●View history
  







Tools
    


Actions  


●Read
 ●Edit
 ●View history
  



General  


●What links here
 ●Related changes
 ●Upload file
 ●Special pages
 ●Permanent link
 ●Page information
 ●Cite this page
 ●Get shortened URL
 ●Download QR code
 ●Wikidata item
  



Print/export  


●Download as PDF
 ●Printable version
  















Appearance
    

 





From Wikipedia, the free encyclopedia
  

Pegsunercept
Clinical data
Routes of
administration		subcutaneous injection
ATC code
  • none
Legal status
Legal status
  • investigational
Pharmacokinetic data
BioavailabilityN/A
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC502H758N154O165S16
Molar mass12103.46 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Pegsunercept is a drug for the treatment of rheumatoid arthritis. As of January 2010, Phase II clinical trials have been completed.[1][2][3] It is being developed by Amgen.

Similarly to etanercept, pegsunercept is a soluble tumor necrosis factor receptor. Pegsunercept is a PEGylated protein.[3]

References[edit]

  1. ^ Clinical trial number NCT00037700 for "Evaluation of the Efficacy of Combination Treatment With Anakinra and Pegsunercept in Improving Rheumatoid Arthritis" at ClinicalTrials.gov
  • ^ Clinical trial number NCT00111423 for "Evaluating the Safety of Extended Treatment With Pegsunercept (PEG sTNF-RI)in Subjects With Rheumatoid Arthritis (RA)" at ClinicalTrials.gov
  • ^ a b Furst DE, Fleischmann R, Kopp E, Schiff M, Edwards C, Solinger A, Macri M (December 2005). "A phase 2 dose-finding study of PEGylated recombinant methionyl human soluble tumor necrosis factor type I in patients with rheumatoid arthritis". The Journal of Rheumatology. 32 (12): 2303–10. PMID 16331754.
    • Stub icon

    This antineoplasticorimmunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

  • t
  • e

    • Retrieved from "https://en.wikipedia.org/w/index.php?title=Pegsunercept&oldid=1192772866"
    Categories: 
    ●Drugs not assigned an ATC code
     ●TNF inhibitors
     ●Immunosuppressants
     ●Amgen
     ●Antineoplastic and immunomodulating drug stubs
     Hidden categories: 
    ●Articles with short description
     ●Short description matches Wikidata
     ●Drugs with non-standard legal status
     ●Articles with changed CASNo identifier
     ●Chemicals that do not have a ChemSpider ID assigned
     ●Infobox drug articles without a structure image
     ●Articles without EBI source
     ●Chemical pages without DrugBank identifier
     ●Articles without InChI source
     ●Drugboxes which contain changes to verified fields
     ●Articles containing potentially dated statements from January 2010
     ●All articles containing potentially dated statements
     ●All stub articles
      


    ●This page was last edited on 31 December 2023, at 06:59 (UTC).
    ●Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.


    ●Privacy policy
    ●About Wikipedia
    ●Disclaimers
    ●Contact Wikipedia
    ●Code of Conduct
    ●Developers
    ●Statistics
    ●Cookie statement
    ●Mobile view


    Wikimedia Foundation
    Powered by MediaWiki